{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:26:25Z","timestamp":1793125585457,"version":"4.5.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,8,14]]},"DOI":"10.3233\/jad-170056","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T11:41:55Z","timestamp":1502192515000},"page":"1393-1413","source":"Crossref","is-referenced-by-count":28,"title":["Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A\u03b2PPswe Mice Without Inducing Microhemorrhage"],"prefix":"10.1177","volume":"59","author":[{"given":"Stephanie","family":"Villarreal","sequence":"first","affiliation":[{"name":"Neuroscience, MRL, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Imaging, MRL, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn A.","family":"Hyde","sequence":"additional","affiliation":[{"name":"Pharmacology, MRL, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Holder","sequence":"additional","affiliation":[{"name":"Biostatistics, MRL, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forest","sequence":"additional","affiliation":[{"name":"Safety Assessment and Laboratory Animal Research, MRL, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sondey","sequence":"additional","affiliation":[{"name":"Pharmacology, MRL, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmacology, MRL, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Sur","sequence":"additional","affiliation":[{"name":"Imaging, MRL, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Parker","sequence":"additional","affiliation":[{"name":"Pharmacology, MRL, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Neuroscience, MRL, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-170056_ref1","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"Discovery of Verubecestat (MK-8931), a BACE1 inhibitor that dramatically reduces CNS A\u03b2 levels in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-170056_ref2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-170056_ref3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-170056_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt59","article-title":"Autosomal-dominant Alzheimer\u2019s disease: A review and proposal for the prevention of Alzheimer\u2019s disease","volume":"3","author":"Bateman","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-170056_ref5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","article-title":"BACE1 Physiological functions may limit its use as therapeutic target for Alzheimer\u2019s disease","volume":"39","author":"Barao","year":"2016","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-170056_ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-170056_ref7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","article-title":"A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease","volume":"76","author":"Karran","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170056_ref8","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-170056_ref9","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: A historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-170056_ref10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-160122","article-title":"Amyloid-Related Imaging Abnormalities (ARIA) in immunotherapy trials for Alzheimer\u2019s disease: Need for prognostic biomarkers?","volume":"52","author":"Piazza","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-170056_ref11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.3233\/JAD-170056_ref12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170056_ref13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.3233\/JAD-170056_ref14","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","article-title":"Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170056_ref15","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170056_ref16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-170056_ref17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","article-title":"Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage","volume":"1","author":"Wilcock","year":"2004","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-170056_ref18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","article-title":"Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta","volume":"25","author":"Racke","year":"2005","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref19","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/jpet.110.172932","article-title":"Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice","volume":"335","author":"Luo","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-170056_ref21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.3233\/JAD-170056_ref22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1523\/JNEUROSCI.4936-10.2011","article-title":"Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer\u2019s disease: Application to passive Abeta immunotherapy","volume":"31","author":"Beckmann","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref23","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1523\/JNEUROSCI.0540-14.2014","article-title":"CNS amyloid-\u03b2, soluble APP-\u03b1 and -\u03b2 kinetics during BACE inhibition","volume":"34","author":"Dobrowolska","year":"2014","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","article-title":"Cerebral microbleeds: A guide to detection and interpretation","volume":"8","author":"Greenberg","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170056_ref25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF00635884","article-title":"Capillary density measurements in skeletal muscle using immunohistochemical staining with anti-collagen type IV antibodies","volume":"71","author":"Madsen","year":"1995","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"10.3233\/JAD-170056_ref26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4081\/881","article-title":"A novel staining method for quantification and 3D visualisation of capillaries and muscle fibres","volume":"48","author":"Cebasek","year":"2004","journal-title":"Eur J Histochem"},{"key":"10.3233\/JAD-170056_ref27","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","article-title":"Immunotherapy reduces vascular amyloid beta in PDAPP mice","volume":"28","author":"Schroeter","year":"2008","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref28","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","article-title":"Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition","volume":"24","author":"Wilcock","year":"2004","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","article-title":"Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration","volume":"15","author":"Wilcock","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-170056_ref30","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","article-title":"Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice","volume":"26","author":"Wilcock","year":"2006","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-170056_ref31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-2094-3-11","article-title":"Intracranial administration of deglycosylatedC-terminalspecific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice","volume":"3","author":"Carty","year":"2006","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-170056_ref32","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.1073\/pnas.1220748110","article-title":"BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells","volume":"110","author":"Rochin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-170056_ref33","doi-asserted-by":"crossref","first-page":"21917","DOI":"10.1038\/srep21917","article-title":"Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice","volume":"6","author":"Shimshek","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-170056_ref34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.115.230565","article-title":"Systems pharmacology analysis of the amyloid cascade after \u03b2-secretase inhibition enables the identification of an A\u03b242 oligomer pool","volume":"357","author":"van Maanen","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-170056_ref35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1186\/1750-1326-9-28","article-title":"Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: Interplay with cerebral blood flow","volume":"9","author":"Li","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-170056_ref36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-170056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:18Z","timestamp":1777370658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-170056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":36,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-170056","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]}}}